NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BTIG Upgrades Neogenomics (NEO) to Buy
October 27, 2016 7:26 AM EDTBTIG upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $10. Analyst Sean Lavin sees a compelling entry point.
"When we downgraded shares at $9, our view was that a fair amount of good news had been priced in easing reimbursement... More
